BR112015001352A2 - POLYPEPTIDE, CHIMERIC PROTEIN, POLYNUCLEOTIDE, VECTOR, CELL CULTURE, COMPOSITION, AND USES OF A CHIMERIC PROTEIN AND COMPOSITION - Google Patents
POLYPEPTIDE, CHIMERIC PROTEIN, POLYNUCLEOTIDE, VECTOR, CELL CULTURE, COMPOSITION, AND USES OF A CHIMERIC PROTEIN AND COMPOSITIONInfo
- Publication number
- BR112015001352A2 BR112015001352A2 BR112015001352A BR112015001352A BR112015001352A2 BR 112015001352 A2 BR112015001352 A2 BR 112015001352A2 BR 112015001352 A BR112015001352 A BR 112015001352A BR 112015001352 A BR112015001352 A BR 112015001352A BR 112015001352 A2 BR112015001352 A2 BR 112015001352A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- chimeric protein
- polypeptide
- polynucleotide
- vector
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
POLIPEPTÍDEO, PROTEÍNA QUIMÉRICA, POLINUCLEOTÍDEO, VETOR, CULTURA DE CÉLULA, COMPOSIÇÃO, E, USOS DE UMA PROTEÍNA QUIMÉRICA E DE UMA COMPOSIÇÃO. A invenção refere-se a uma proteína quimérica compreendendo ou consistindo em, desde a terminação-N até a terminação-C, (a) uma parte N-terminal de uma proteína CyaA de Bordetella (b) um polipeptídeo heterólogo compreendendo antígenos que se originam de HPVs diferentes, e (c) uma parte C-terminal de uma proteína CyaA de Bordetella. A invenção também se refere a um polinucleotídeo que codifica esta proteína quimérica. Uma composição compreendendo pelo menos uma(s) proteína(s) quimérica(s) da invenção e os usos profiláticos e/ou terapêuticos de dita composição também são parte da invenção.POLYPEPTIDE, CHIMERIC PROTEIN, POLYNUCLEOTIDE, VECTOR, CELL CULTURE, COMPOSITION, AND, USES OF A CHIMERIC PROTEIN AND COMPOSITION. The invention relates to a chimeric protein comprising or consisting of, from the N-terminus to the C-terminus, (a) an N-terminal part of a Bordetella CyaA protein (b) a heterologous polypeptide comprising antigens that originate from different HPVs, and (c) a C-terminal part of a Bordetella CyaA protein. The invention also relates to a polynucleotide encoding this chimeric protein. A composition comprising at least one chimeric protein(s) of the invention and the prophylactic and/or therapeutic uses of said composition are also part of the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305898.4A EP2689786A1 (en) | 2012-07-23 | 2012-07-23 | HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders |
EP2014016312 | 2014-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015001352A2 true BR112015001352A2 (en) | 2022-06-28 |
Family
ID=83355827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015001352A BR112015001352A2 (en) | 2012-07-23 | 2013-07-23 | POLYPEPTIDE, CHIMERIC PROTEIN, POLYNUCLEOTIDE, VECTOR, CELL CULTURE, COMPOSITION, AND USES OF A CHIMERIC PROTEIN AND COMPOSITION |
Country Status (1)
Country | Link |
---|---|
BR (1) | BR112015001352A2 (en) |
-
2013
- 2013-07-23 BR BR112015001352A patent/BR112015001352A2/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
SA520412669B1 (en) | Manufacture of Recombinant Clostridium Botulinum Neurotoxins | |
PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
MX2017006866A (en) | Fusion partners for peptide production. | |
MX2016008782A (en) | Fc-region variants with improved protein a-binding. | |
GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
MX2019008803A (en) | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof. | |
TN2014000360A1 (en) | Cx3cr1-binding polypeptides | |
MX2021001460A (en) | Methods and compositions for secretion of heterologous polypeptides. | |
MX2021008318A (en) | Novel specific-binding polypeptides and uses thereof. | |
MX359315B (en) | Dna vaccine for use in pancreatic cancer patients. | |
BR112017020308A2 (en) | udp-glycosyltransferases | |
EP4011906A3 (en) | Lactase enzymes with improved properties | |
BR112018001121A2 (en) | recombinant orf virus vector (orfv), cell, composition, use of an orfv recombinant vector, and nucleic acid molecule | |
BR112015003724A2 (en) | isolated polypeptide, composition, use of a composition, isolated polynucleotide, nucleic acid construct or expression vector, recombinant host cell, and methods of producing a polypeptide and producing a protein. | |
MY173686A (en) | Fc gamma receptor iib variants | |
BR112017001463A2 (en) | improved host cell to produce proteins | |
BR112015001350A2 (en) | polynucleotide, chimeric polynucleotide, polynucleotide use, vector, cell culture, cyaa-derived protein, chimeric protein, composition, and method for producing a chimeric protein | |
WO2014170460A3 (en) | Method for the production of collagen proteins derived from marine sponges and an organism able to produce said proteins | |
AU2018277310A1 (en) | Aggrecan binding immunoglobulins | |
MX2017003729A (en) | Statherin peptides. | |
TR201900695T4 (en) | HPV / CYAA-BASED CHEMICAL PROTEINS AND THEIR USE IN INDUCING IMMUNE RESPONSE AGAINST HPV INFECTION AND HPV-INDUCED DISASTER. | |
MX2018003445A (en) | Expression of fc-containing proteins. | |
BR112015001352A2 (en) | POLYPEPTIDE, CHIMERIC PROTEIN, POLYNUCLEOTIDE, VECTOR, CELL CULTURE, COMPOSITION, AND USES OF A CHIMERIC PROTEIN AND COMPOSITION | |
MX2016017094A (en) | Clostridium difficile immunogenic composition. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2687 DE 05-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |